Oxytrol OTC Success Depends On Driving Behavioral Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s Oxytrol for Women could set the stage for other OTC switches indicated for chronic conditions, but the lifestyle changes recommended with the drug could be a hurdle. Oxytrol faces similar challenges to alli, another first-in-class switch with behavioral changes recommended.
You may also be interested in...
UK Looks To Switch Overactive Bladder Treatment
Maxwellia is seeking its second first-in-class switch in the UK with an application to reclassify from prescription-only to pharmacy status overactive bladder treatment Aquiette.
Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts
Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.
Glaxo "Shakes Up" Alli Ad Strategy With New Agency
GlaxoSmithKline's decision to reassign the advertising contract for its alli OTC weight-loss drug two years after the product's launch could point to a fundamental problem with the brand's message, according to Steven Brozak, an investment banker working with biotech, medical device and health care firms